When a preferred cannabis stock, Edmonton, Alberta-based Aurora Marijuana( NYSE: ACB) saw its worst days in 2019, with decreasing incomes, negative profitability, and a sinking leadership group ultimately pushing its stock to the brink of being delisted. Its share rate fell listed below $1, which protests the trading compliance of the New York Stock Exchange; it just saved itself through a reverse stock split.
This year, that stock split and its better-than-expected third-quarter results appear to be helping Aurora make a great deal of noise.
Image Source: Getty Images.
Working its way up
Aurora marked its entry into the U.S. cannabidiol (CBD) market by obtaining hemp-derived CBD company Reliva in May. Aurora’s entry could offer Canopy Growth( NYSE: CGC) tough competition in the U.S. CBD market; the latter business has currently released different cannabis-infused beverages with the help of its collaboration with Constellation Brands.
Aurora saw 16%year-over-year profits development to 75.5 million Canadian dollars in its third quarter, much to everyone’s surprise. Both customer cannabis earnings and medical marijuana revenue showed surprising sequential growth.
In spite of impressing financiers with those numbers, Aurora failed to accomplish positive incomes before interest, tax, devaluation, and amortization (EBITDA) in the 3rd quarter. That stated, during the third-quarter earnings call, management guaranteed financiers that they were working to decrease selling, general, and administrative (SG&A) expenses and hit positive EBITDA by the first quarter of2021
Cost-cutting measures to strike profitability
To acquire financiers’ self-confidence and show how severe they are about striking their targets, Aurora announced some operational changes on June23
Cutting the workforce is never good news.; typically, it’s the last hope a company can take to save expenses. But given the state of affairs at Aurora, management made the tough choice to drop 25%of SG&A staff efficient instantly, as well as about 30%of production personnel over the next 2 quarters.
Aurora likewise made some restructuring changes at the executive leadership level, including the retirement of president Steve Dobler. These modifications will help it attain an SG&A run rate of CA$42 million by the first quarter of 2021, which management hopes will support greater levels of revenue in the future.
Aurora also prepares to close five of its small facilities over the next two quarters– particularly Aurora Meadow (in Saskatchewan), Aurora Mountain (in Alberta), Aurora Ridge (in Ontario), and Aurora Vie and Aurora Eau (both in Quebec). It likewise intends to consolidate its Canadian production and production at the Aurora Sky and Aurora Polaris (both in Alberta), Aurora River (in Ontario), and Whistler Pemberton (in British Columbia) centers by the 2nd quarter of2020
These facility changes could cost Aurora– possession disability charges connected to production might amount to CA$60 million and inventory writedown charges might reach CA$140 million in the fourth quarter of2020 Aurora hopes to see enhanced gross margins thanks to these steps.
Management appeared hopeful, stating in a news release, “We believe that we now have the best balance for the long-term success of Aurora– market leadership, monetary discipline, functional excellence, and strong execution. We remain concentrated on making Aurora a rewarding and robust worldwide cannabinoid business.”
Aurora’s strong move has definitely satisfied analysts, much of whom have upgraded the stock and increased its target price.
Will the efforts settle?
A reverse stock split generally gives a stock a quick bounce from short-term gains, but the delighted days normally end quickly. In Aurora’s case, however, a string of favorable news appears to be benefiting the stock. It has risen 78.1%since its split on May 11, while the Horizons Marijuana Life Sciences ETF– the benchmark marijuana index– has risen by 13.9%in the same period.
Last month’s Reliva acquisition looked like a bold relocation for a business that is strained with debt, the item of its careless decisions during an acquisition spree last year.
We will know more about whether Aurora’s strategies are settling when it reports its fourth-quarter fiscal 2020 results in September. Financiers ought to proceed with caution when it comes to this cannabis stock
Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands. The Motley Fool has a disclosure policy.